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Methods for Scarless, Selection-
Free Generation of Human Cells and 
Allele-Specific Functional Analysis 
of Disease-Associated SNPs and 
Variants of Uncertain Significance
Nicole B. Coggins, Jacob Stultz, Henriette O’Geen, Luis G. Carvajal-Carmona   
& David J. Segal  
With the continued emergence of risk loci from Genome-Wide Association studies and variants of 
uncertain significance identified from patient sequencing, better methods are required to translate 
these human genetic findings into improvements in public health. Here we combine CRISPR/Cas9 
gene editing with an innovative high-throughput genotyping pipeline utilizing KASP (Kompetitive 
Allele-Specific PCR) genotyping technology to create scarless isogenic cell models of cancer variants 
in ~1 month. We successfully modeled two novel variants previously identified by our lab in the PALB2 
gene in HEK239 cells, resulting in isogenic cells representing all three genotypes for both variants. We 
also modeled a known functional risk SNP of colorectal cancer, rs6983267, in HCT-116 cells. Cells with 
extremely low levels of gene editing could still be identified and isolated using this approach. We also 
introduce a novel molecular assay, ChIPnQASO (Chromatin Immunoprecipitation and Quantitative 
Allele-Specific Occupation), which uses the same technology to reveal allele-specific function of these 
variants at the DNA-protein interaction level. We demonstrated preferential binding of the transcription 
factor TCF7L2 to the rs6983267 risk allele over the non-risk. Our pipeline provides a platform for 
functional variant discovery and validation that is accessible and broadly applicable for the progression 
of efforts towards precision medicine.
In the past decade, Genome-Wide Association Studies (GWAS) have identified a large number of genomic vari-
ants, specifically single nucleotide polymorphisms (SNPs), associated with increased disease risk. The molecular 
mechanisms underlying the vast majority of these associations remain largely unknown1,2. In parallel, the dimin-
ishing cost of next-generation sequencing (NGS) has led to a rapid expansion in whole-genome, whole-exome 
and multi-gene panel sequencing of clinical populations3,4. Novel variants of uncertain significance (VUSs) in 
moderate-to-high penetrance genes are being identified with increasing frequency. However, without functional 
data for these variants there are few actions that can be taken to inform patient care3,4. In both cases, cellular 
models containing the variant of interest could be a crucial tool in establishing disease-relevant function and 
beginning the path towards application in precision medicine5,6. CRISPR/Cas9 gene editing has provided a con-
venient and flexible method for creating isogenic cell lines, which would, in principle, differ by only one engi-
neered variant. However, while CRISPR/Cas9 has become the gold standard for targeted gene knockouts by the 
error-prone but highly efficient non-homologous end-joining (NHEJ) pathway7,8, it has been more difficult to 
create changes by the highly precise but less efficient homology-directed repair (HDR) and single-stranded tem-
plate repair (SSTR) pathways (still < 1% in many cell types)9–12. In addition, the process for the isolation of cells 
that have received the desired mutation has proved cumbersome. A common strategy is the use of selectable 
markers, such as antibiotic resistance and fluorescent proteins, to find and purify the rare appropriately modified 
cells5,13. However, the introduction and even subsequent elimination of such elements often leads to “scarring” 
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of the genome, such as a loxP site remaining after Cre-mediated excision14. Scarring methods might be accept-
able for certain types of genetic alterations such as truncating mutations in exons. However, the vast majority of 
risk-associated SNPs occur in noncoding intergenic or intronic regions, with very little information concerning 
the phenotypic significance of any base in the vicinity1,2. Likewise, most VUSs, while located in protein coding 
regions, are missense, non-truncating mutations15. Therefore, better methods are required for precision editing to 
become a useful and efficient approach for the functional analysis of the numerous SNPs and VUSs.
In response to this need, we have developed a time/cost-effective and widely accessible pipeline to create 
and isolate scarless isogenic cell lines for the downstream functional testing of a precise variant of interest. Our 
pipeline takes advantage of the KASP (Kompetitive Allele Specific PCR, LGC Group) genotyping platform paired 
with single- or multi-cell cloning in a 96-well format. KASP genotyping is based on a competitive PCR with a 
common primer and two allele-specific primers, one for the wildtype allele and the other for the putative func-
tional/mutant allele. Unlike expensive TaqMan probes, these primers are unmodified oligos that contain a com-
plimentary sequence for the annealing of FAM or HEX fluorochromes in the KASP PCR master mix. Because of 
this, KASP primers can be synthesized quickly and at low-cost. The design also allows for the multiplexed detec-
tion of multiple variants on a single 384-well plate, allowing for cost- and time-efficient production of isogenic 
cell lines. In this study, we use our pipeline to produce isogenic cell models of two novel VUSs and one colorectal 
cancer (CRC) risk SNP that were identified in our previous studies16,17.
As a downstream functional assay of this pipeline, we also present a novel method to detect and quantitate 
allele-specific regulatory effects of noncoding variants utilizing the same KASP technology. Recent studies have 
used existing Chromatin Immunoprecipitation paired with High-Throughput Sequencing (ChIP-Seq) data sets 
to show that many risk-associated SNPs identified by GWAS are located within transcription factor binding sites 
and that risk status of these SNPs may alter binding of said transcription factors, ultimately affecting overall tran-
scriptional regulation within the cell2,18,19. However, for many cancer risk-associated GWAS SNPs, effect size is 
often small, increasing per-allele odds ratio of disease by less than 1.0 for the risk allele compared to non-risk1. As 
such, functional differences between cellular models of genotypes for a risk SNP may also be subtle. In order to 
better dissect the functional mechanism of these single nucleotide variants, an assay that measures allelic effects 
is a necessary addition to established assays that measure genotypic effect. In other words, an assay that can detect 
differences in function between a risk and a non-risk allele within the same cell could provide a more sensitive 
platform for functional variant validation than assays that can only compare across genotypes. Our novel molec-
ular assay Chromatin Immunoprecipitation and Quantitative Allele-Specific Occupation or ChIPnQASO pairs 
standard ChIP with KASP genotyping technology to allow for quantitation of these allelic effects. We demonstrate 
the power of this novel assay in the detection and quantification of allelic binding preference for transcription 
factor TCF7L2 and chromatin insulating protein CTCF within edited HCT-116 clones that are heterozygous for 
the risk SNP rs6983267 produced from our pipeline. ChIPnQASO offers a sensitive and high-throughput method 
for detection of transcription factor binding allelic imbalances at disease risk loci.
Results
We used HEK293 cells to create isogenic cell models of two VUSs identified from a gastric cancer cohort in 
the PALB2 locus, a single-base substitution (PALB2-SNV) and a 9-base in-frame deletion (PALB2-DEL)16. The 
process from guide RNA (gRNA) design to identification of positive clones took ~1 month (Fig. 1a). Plasmid 
DNA expressing wildtype Cas9 and gRNAs with on-target activity confirmed by T7 endonuclease I assay were 
co-transfected with a 127-nt single-stranded oligonucleotide donor (ssDonor) for either the single base substi-
tution or the 9-base deletion (Fig. 1b,c; Supplementary Fig. 1a). Single cells were seeded in 96-well plates and 
expanded as described in the Methods and Supplementary Fig. 6. Genomic DNA was analyzed using the KASP 
genotyping system, which only required 10 ng of genomic DNA per clone. Each run was performed in a 384-well 
plate on a real-time PCR system (Biorad, Hercules, CA), allowing for the identification of correctly edited isogenic 
clones to be completed in a matter of hours. KASP genotyping results are visualized as a cluster plot in which 
the relative fluorescence for both the putative functional/mutant and wildtype alleles is measured on each axis 
(Fig. 1d,e, right). The genotype of each isogenic clone can then be inferred via clustering with genotype controls. 
Because of the design of the allele-specific primers, clones possessing alleles exhibiting NHEJ events near the vari-
ant of interest will result in an inability for either allele-specific primer to bind. Thus, genomic DNA of clones with 
NHEJ events will not amplify and will cluster with the no template controls (Fig. 1d,e, right, black dots). Notably, 
we were able to obtain multiple clones for all three genotypes from the screening of only 48 PALB2-SNV clones 
and 57 PALB2-DEL clones, an allelic efficiency of 8.3% and 9.6%, respectively (Fig. 1d,e; Table 1a). Genotypes of 
all mutant clones were confirmed by Sanger sequencing (Supplementary Fig. 2).
To demonstrate a broader application of the cell-screening pipeline, we created isogenic cell lines to model the 
CRC GWAS risk SNP rs6983267 on chromosome 8q24, which has been previously shown to cause differential 
binding of a key WNT pathway transcription factor, TCF7L220,21. HCT-116 is a CRC line that is homozygous for 
the rs6983267 risk (G) allele. To create isogenic cell models that would contain one or more reference (T) alleles, 
plasmids expressing wildtype Cas9 and gRNA, were co-transfected with a 70-bp ssDonor containing the reference 
allele with homology arms symmetrically centered around the SNP (Fig. 2a; Supplementary Fig. 1b). We screened 
101 clones and identified 5 heterozygous clones, an HDR efficiency of 2.6%, confirmed by Sanger sequencing 
(Table 1b; Supplementary Fig. 3b). In an effort to improve HDR efficiency, we compared symmetric ssDonors 
with the more recently described asymmetric donors22. Interestingly, NGS of cells treated with nuclease and these 
two ssDonors showed that the asymmetric donor did not increase the number of HDR events in these cells, but 
instead greatly decreased the number of NHEJ events in comparison to the symmetric donor, 3.6% and 16.5% for 
asymmetric and symmetric respectively (Supplemental Fig. 4). This could have been due to the lack of a robust 
Fanconi Anemia repair pathway in HCT-116 cells12.
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As an even further extension of the application of this pipeline, we wanted to test its ability to detect 
single-base changes for cell types with extremely low HDR frequency, low transfection efficiency or an inability to 
grow from single cells. This required first testing the sensitivity of mutant allele detection of the KASP genotyping 
platform. By combining genomic DNA of wildtype HCT-116 cells with that of our newly created heterozygous 
clones (G/T) at varying ratios, we were able to determine the KASP genotyping platform could detect the pres-
ence of the mutant (T) allele at concentrations as low as 5% (Supplementary Fig. 5). In light of these results, we 
hypothesized that the KASP genotyping platform could be used to detect HDR-positive alleles even in a cell pop-
ulation with mixed genotypes. To test this, we performed multi-cell cloning for the risk SNP rs6983267, in which 
10 cells were seeded per well in 96-well plates post-transient transfection instead of single cells. We chose 10-cell 
per well plating as the allelic ratio of 1 mutant allele among 19 wildtype alleles was within the 5% mutant allele 
Figure 1. Scarless genome editing in HEK239 cells modeling Gastric Cancer novel VUSs, a single-base 
substitution (PALB2-SNV) and a 9-base deletion (PALB2-DEL) in the PALB2 gene. (a) Timeline of CRISPR-
Cas9 mediated HDR followed by KASP clonal genotyping pipeline to isogenic clones. (b,c) CRISPR-Cas9 HDR 
strategy and KASP mutation detection probes with mutation of interest (black nucleotides), guide RNA (red 
line), PAM site (red nucleotides), cleavage sites (red triangles) and 127-bp single-stranded asymmetric donor 
template for SNV and 9-base deletion respectively. (d,e) Isogenic clone plating in 96-well plate format and KASP 
genotyping cluster output of single-cell clones color-coded by genotype, Mut/Mut (blue), Mut/WT (orange), 
WT/WT (green) and no template controls (black) for SNV and 9-base deletion respectively.
a.
PALB2-SNV
WT/WT WT/Mut Mut/Mut Total Clones
42 4 2 48
87.5% 8.3% 4.7%
PALB2-DEL
WT/WT WT/Mut Mut/Mut Total Clones
50 3 4 57
87.7% 5.3% 7.0%
b.
8q24-SNP Single-Clones
WT/WT WT/Mut Mut/Mut Total Clones
96 5 0 101
95.0% 5.0% 0.0%
Table 1. Isogenic clone frequencies for each genotype produced from pipeline for Gastric Cancer VUSs PALB2-
SNV and PALB2-DEL in HEK293 cells and for Colorectal Cancer Risk SNP rs6983267 in HCT-116 cells.
www.nature.com/scientificreports/
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detection ability of the KASP genotyping platform, allowing us to produce multi-cell-of-origin clones that could 
still be screened for precise HDR events. We predicted that multi-cell clones with cells that were positive for the 
correct HDR event would appeared as a distinct cluster between the homozygous wildtype and the heterozygous 
clusters on the KASP output. Indeed, we screened 53 multi-cell clones and were able to identify two clones that 
clustered distinctly, from here on referred to as Multi 1 and Multi 2 (Fig. 2b). For these clones, TOPO TA cloning 
was required to confirm the presence of alleles with only the precise HDR event and free of NHEJ events. For each 
multi-cell clone, we screened 24 to 32 TOPO TA colonies, where each colony was representative of a single allele 
in the mixed population, with Sanger sequencing following PCR amplification (Supplementary Fig. 7a,b). Our 
results show that only Multi 2 contained scarlessly modified alleles, while Multi 1 contained mixed NHEJ and 
HDR alleles (Fig. 2c; Supplementary Fig. 7c; Supplementary Table 1). Because of that, only Multi 1 was expanded 
and put through a second round of cloning, in which cells of Multi 1 were plated at a single-cell per well in a 
single 96-well plate in order to isolate the correctly edited cells. This produced a number of isogenic clones that 
were scarlessly heterozygous (G/T) for rs6983267 (data not shown). Our success with both single-cell-of-origin 
and multi-cell-of-origin cloning to produce scarless isogenic clones positive for a precise HDR event proves the 
flexibility of this pipeline for use in many different cell types, even those with extremely low HDR efficiency or an 
inability to grow from a single-cell (Supplementary Fig. 8).
It has been predicted that many noncoding GWAS SNPs function by affecting a transcription factor binding 
site within which they are located, causing an increase or decrease in the binding occupancy of the factor2,18,19. 
Such a function has been previously described for CRC risk SNP rs6983267, which is located within a binding 
site for transcription factor TCF7L220,21. To better address this mechanism of function, we developed a method 
to assess allele-specific binding of DNA binding proteins in a quantitative manner. This method, Chromatin 
Immunoprecipitation and Quantitative Allele-Specific Occupation or ChIPnQASO, performs a standard 
Figure 2. Multi-cell cloning to produce scarless single-base genome editing modeling Colorectal Cancer 
risk SNP rs6983267 in HCT-116 cells. (a) CRISPR-Cas9 HDR strategy and KASP mutation detection probes 
with mutation of interest (black nucleotides), guide RNA (red line), PAM site (red nucleotides), cleavage sites 
(red triangles) and 70-bp single-stranded symmetric donor template centered around risk SNP. (b) KASP 
genotyping cluster output of multi-cell clones produced from 10-cell per well seeding in 96-well plates (red) 
with genotyping controls: Mut/Mut (blue), Mut/WT (orange), WT/WT (green) and no template controls 
(black). Black arrows indicate multi-cell clones, Multi 1 and Multi 2, that form a distinct 4th cluster between 
the homozygous wildtype and heterozygous clusters, indicating these clones contain HDR-positive cells. (c) 
Alignment of sanger sequencing of correct-sized TOPO TA colony PCR amplicons grouped by allele for Multi 
2. Reference sequence indicates unmodified HCT-116 sanger sequence. Arrow indicates location of risk SNP. 
Allele 9 displays desired scarless single-base substitution. Thus, Multi 2 was expanded for a second round of 
limiting dilution at single-cell per well seeding concentration to produce isogenic heterozygous clones.
www.nature.com/scientificreports/
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chromatin Immunoprecipitation on cells that are heterozygous for the variant of interest, and then uses KASP 
genotyping to quantitate the relative amounts of the two alleles in the precipitated DNA (Fig. 3a). If the tran-
scription factor exhibits preferential binding to one allele, the precipitated DNA will cluster in a genotyping plot 
nearer the preferred allele and not with the input DNA, which should contain equal ratios of both alleles (Fig. 3c). 
To demonstrate the application of ChIPnQASO, we chose to use our heterozygous models of the CRC SNP 
rs6983267, whose risk allele (G) has been shown to preferentially bind the TCF7L2 transcription factor over the 
reference (T) allele (Fig. 3b)20,21. We used ChIPnQASO to analyze both the TCF7L2 binding site and an adjacent 
CTCF binding site, which we hypothesized to not demonstrate allelic binding preference as it is located further 
from the risk SNP, for differential allelic binding. Indeed, we observed a 2:1 preference of TCF7L2 for the G allele 
in our clones (Fig. 3c,d). As hypothesized, we also did not observe an allelic preference for CTCF binding at the 
SNP-adjacent site, suggesting that CTCF function at this locus is unaffected by rs6983267 risk status in these cells. 
ChIPnQASO provides an important addition to the established assays that compare differences between cells of 
different genotype, allowing for assessment of allelic effect as well. Furthermore, ChIPnQASO is distinct in its 
ability to assess multiple transcription factors at multiple heterozygous loci simultaneously within the same cell.
Discussion
In this study, we have presented a novel pipeline based on KASP genotyping for generating scarless isogenic cell 
models of SNPs and VUSs for functional studies. The method provides sensitive identification of low frequency 
HDR events, and was able to generate isogenic cell lines modeling all three genotypes for a given variant in approx-
imately one month without selectable markers, specialized equipment such as digital droplet PCR (ddPCR), or 
next-generation sequencing23,24. The pipeline is also useful to create models in cells for which single-cell cloning is 
Figure 3. Allele-specific functional analysis of risk SNP rs6983267 within heterozygous HCT-116 clones 
using KASP genotyping technology. (a) Overview of the allele-specific applications of KASP genotyping: allele 
genotyping of nuclease-modified clones, relative allele-specific expression of RNA transcripts harboring a 
heterozygous mutation and relative allele-specific binding affinity of DNA binding proteins that bind on or in 
the vicinity of a heterozygous mutation. (b) Diagram of heterozygous 8q24 risk locus with transcription factor 
TCF7L2 (red) and insulating protein CTCF (purple) with binding motifs depicted as black boxes. Risk SNP is 
located immediately adjacent to the core TCF7L2 binding motif (TCAAAG). (c) KASP fluorescence ratio output 
of TCF7L2 and CTCF binding at 8q24 locus between G allele and T allele in heterozygous clones (n = 3) run 
in duplicate with input genomic DNA (orange), immunoprecipitated DNA for TCF7L2 (red), CTCF (purple) 
and IgG (gray) and no DNA template controls (black). CTCF IPed DNA samples cluster with Input DNA while 
TCF7L2 IPed DNA samples create a separate cluster favoring the G allele compared to Input DNA. (d) Allelic 
ratios of G (green) and T (blue) alleles in percentage of total fluorescence for input control, TCF7L2 and CTCF, 
quantifying G-allele allelic preference of TCF7L2 compared to CTCF relative to Input DNA control. Errors bars 
show standard deviation.
www.nature.com/scientificreports/
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not possible. In these cases, multiple treated cells can be cultured in a single well (Supplementary Fig. 8). For this 
application, the use of multiple rounds of selection and expansion of mixed colonies in which the mutant allele is 
detected would be required to enrich for the mutation of interest, similar to the ddPCR and sib-selection method 
previously described by Conklin and co-workers23. However, our pipeline does not require the use of a ddPCR, 
which is more expensive, complex to operate and less available than standard qPCR systems.
The KASP genotyping method is expected to generate very few false negative results in which a correctly 
edited allele would be missed. However, we have observed two possibilities of false positives. Isogenic clones 
with one correctly modified allele and the other harboring an NHEJ event would cluster with the homozygous 
mutant allele on the genotype plot, albeit at half the fluorescent signal strength. Likewise, isogenic clones contain-
ing an allele with an NHEJ event that mimics the expected genomic edit would falsely cluster with HDR-edited 
cells on the KASP output. For example, if the expected HDR event is to substitute a T for a G, and there was an 
NHEJ-induced deletion that brings a T into the exact position the substitution was supposed to occur, the results 
would be that the mutant allele-specific primer could potentially still bind to that allele if the orientation of the 
deletion matched the orientation of the allele-specific primers. Although in our experience both events of false 
positives described here are extremely rare, Sanger sequencing to confirm the genotypes of isogenic clones pro-
duced from the KASP system is always a necessary validation step.
In addition to INDEL-induced false positives, there is also the possibility of mosaicism occurring within clones 
seeded from single cell, due to the continued expression of Cas9 and guide RNA after single cell plating. While we 
have not experienced this within our isogenic clones generated from KASP genotyping, we can hypothesize that any 
mosaicism in a single cell colony would be handle by the KASP genotyping in a similar fashion to the multi-cell per 
well plating, in which the genomic DNA of these mixed cell populations would fall between the genotyping control 
clusters. Furthermore, Sanger sequencing to validate the genotypes called by KASP’s cluster plot output is again a 
necessary step and would help to identify any mosaicism that may have occurred after single cell plating.
We also introduced the ChIPnQASO method that uses KASP genotyping to quantitatively measure 
allele-specific chromatin interactions as a downstream functional assay for quantitating allelic effects for GWAS 
risk SNPs within the cellular models produced in our pipeline. While there are other methods that exist to meas-
ure allele-specific binding, such as ChIP followed by Mass Spectrometry or NGS, these methods again require 
access to specialized equipment and personnel19–21. ChIPnQASO, on the other hand, provides a platform in 
which one can assess the allele-specific effects of multiple DNA binding proteins or chromatin marks in mul-
tiple genomic loci simultaneously, producing a high-throughput cost-effective method with the same times-
cale and equipment requirements as an RT-qPCR. In principle, KASP genotyping could also be used for other 
allele-specific analyses, such as allele-specific gene expression (Fig. 3a).
In summary, we present both a method for generating scarless models of disease risk-associated SNPs and 
VUSs without the use of selectable markers as well as a novel molecular assay, ChIPnQASO, for detection and 
quantification of allele-specific effects of non-coding variants located within the binding sites of transcription 
factor and other DNA binding proteins. Both techniques provide improvements on current technologies in their 
ease of use and time and cost-effectiveness, allowing greater accessibility to the CRISPR/Cas9 precision editing 
technology for a many more laboratories. We believe these methods will be useful in understanding the molec-
ular mechanisms of disease-associated SNPs and VUSs, filling a critical gap between association studies and the 
application of precision medicine to the treatment and prevention of disease.
Methods
CRISPR/Cas9 HDR design and cloning. Guide RNAs (gRNAs) were designed for each target mutation 
using the online tool CHOP CHOP (http://chopchop.cbu.uib.no). gRNAs were selected based on in silico predic-
tions of high on-target efficiency, low off-target potential and distance from mutation of interest, with the best 
case scenario being a gRNA whose PAM sequence overlaps with the mutation, thus inhibiting its ability to re-an-
neal with the region after precise editing has been completed. gRNAs were cloned into the gRNA-Cloning Vector 
plasmid from the Church Lab (Addgene Plasmid #41824) via Gibson Assembly (NEB). gRNA plasmids and 
hCas9 vector (Church Lab, Addgene Plasmid #41815) were transformed into NEB 5-alpha competent E. coli cells 
(high efficiency). Plasmids were purified with the Plasmid Plus Midi Kit (Qiagen). Symmetrical single stranded 
(ssDonor) donor template was designed centered around the risk SNP of interest, rs6983267, flanked by 35 bases 
of homology to the non-gRNA-complementary strand of genomic DNA and synthesized by IDT. Asymmetrical 
ssDonors were designed for each gRNA as previously described and synthesized by IDT22.
KASP primer design. KASP primers can be designed using the Primerpicker software (KBiosciences) or cus-
tom ordered directly from the LGC Group (https://www.lgcgroup. com/products/kasp-genotyping-chemistry/). 
The resulting primers sequences, two allele-specific primers of 40–50 bp length named A1 and A2 and two uni-
versal primers of 20–30 bp length named C1 and C2 are reconstituted at a 100uM concentration for use.
Cell culture and transfections. All human cell lines were obtained from ATCC and cultured according to 
ATCC guidelines. HEK293 cells were maintained in DMEM supplemented with 10% Fetal Bovine Serum and 1X 
Penicillin/Streptomycin. HCT-116 cells were maintained in McCoy’s 5 A Medium supplemented with 10% Fetal 
Bovine Serum and 1X Penicillin/Streptomycin. Transfections were carried out in 6-well plates. HEK293 cells were 
seeded at a concentration of 400,000 cells per well and HCT-116 cells at 500,000 cells per well. When the cells 
reached 70% confluency approximately 24 hours later, the cells were transfected with 7.5 μL of Lipofectamine 3000 
(Thermo Fisher Scientific) and either Cas9-NHEJ for T7 Assay: 1ug of hCas9 plasmid, 1ug of guide RNA vector 
plasmid and 1ug of eGFP plasmid (Lonza) per well or Cas9-HDR for cloning: 1ug of hCas9 plasmid, 1ug of guide 
RNA vector plasmid and 800 ng of ssODN donor template per well. Cells were incubated at 37 C with 5% CO2 for 
72 hours, with media replaced after the first 24 hours for HEK239 cells and every 24 hours for HCT-116 cells.
www.nature.com/scientificreports/
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T7 endonuclease I assay. Genomic DNA was harvested from cell 72 hours after Lipofectamine 3000 trans-
fections using the Quick-gDNA MiniPrep Kit (Genesee Scientific). 100 ng of genomic DNA was used for the 
50 μL PCR with 2x High-Fidelity Phusion Master Mix (NEB) and 1.5 μL of 10uM forward and reverse primers 
specific to each guide RNA cutsite. Thermocycler settings are as follows: 95 C for 2 m, (95 C for 15 s, 56 C for 30 s, 
68 C for 1 m) × 35, 72 C for 5 m, 4 C Hold. PCR products were confirmed on a 1% agarose gel and purified using 
QiaQuick PCR Purification Kit (Qiagen). 500 ng of purified PCR product was used in a 19 μL reaction volume 
with 2 μL of 10x NEB2 buffer and randomly re-annealed on the thermocycler with the following settings: 95 C 
for 5 m, 95 C to 85 C at −2C/s ramping, 85 C to 25 C at −2C/s ramping, 4 C Hold. T7 Endonuclease I (NEB, 1 μL) 
was added to each reaction and incubated at 37 C for 45 m. Digestion was run on a 2% agarose gel at 130 V for 
45 m and bands were visualized and quantitated with ImageJ software (NIH). INDEL frequency was calculated 
using the following formula: % INDEL = (1 − (1 − (cut band1 + cut band2)/(cut band1 + cut band2 + uncut 
band))1/2) × 100.
Amplicon sequencing and allele modification analysis. HCT-116 cells were transfected with 
Lipofectamine 3000, plasmid Cas9, plasmid gRNA and either the symmetrical or asymmetrical donor. 
Non-transfected HCT-116 cells were used as a control. 72 hours later, genomic DNA was extracted using 
Quick-gDNA MiniPrep Kit (Genesee Scientific) and 100 ng genomic DNA was used for PCR amplification result-
ing in a 217-bp amplicon. Each forward primer contained a unique 5-bp bar code sequence at the 5′ end for 
multiplexing. All amplicons were purified using QiaQuick PCR Purification Kit (Qiagen) and pooled at equal 
concentrations for Illumina sequencing. Amplicon sequencing was performed by the CCIB DNA Core Facility 
at Massachusetts General Hospital (Cambridge, MA) following their instructions for CRISPR Sequencing. 
Sequencing data was processed using FLASH2 to overlap forward and reverse reads into a single long read. Using 
FASTX barcode splitter, single long reads were demultiplexed by identifying barcodes at the beginning or end of 
the sequence read, allowing for one mismatch. Processed fastq files were analyzed for NHEJ frequency with the 
CRISPResso online tool (http://crispresso.rocks) using default settings. For increased stringency, HDR-positive 
reads were identified from fastq files using the grep function to select reads with 100% homology to the expected 
HDR-positive sequence after 20-bp trimming on either side of the read.
Single-cell limiting dilutions for 96-well plate seeding and colony expansion. Transfected cells 
were resuspended to a single-cell suspension and counted using a hemocytometer. Seeding 2 to 4 96-well plates 
per gRNA targeting a specific mutation was sufficient to produce enough clones for screening and identifying 
HDR-positive clones. For each 96-well plate, 100 cells were added to 10 mL of fresh medium and distributed at a 
100 μL volume per well using a multichannel pipette. Next day, wells were checked for the presence of a single cell. 
Five to seven days later, 100 μL of fresh media was added to each well. Another 5–7 days later, media was changed 
for all wells. Cell colonies were transferred to 24-well plates at 50% confluency. An overview of this process can 
be visualized in Supplementary Fig. 6.
Genomic DNA extraction and KASP genotyping of clones. Cell clones were harvested for genomic 
DNA when they reached 80% confluency in 24-well plates. For this, each clone was dissociated with 100 μL of 
TypLE Express (Thermo Fisher Scientific) and 30 μL of cells were transferred to a new 24-well plate while 70 μL 
were pelleted for genomic DNA extraction. Extraction was performed using the Quick-gDNA MiniPrep Kit 
(Genesee Scientific) eluted into 40 μL Elution Buffer. Genomic DNA was quantified using Qubit 2.0 Fluorometer 
(Thermo Fisher Scientific) producing concentrations between 1–20 ng/μL. KASP genotyping reactions (LGC 
Group) were performed in a 384-well plate as follows: 10 ng genomic DNA, 5 μL 2x KASP Master Mix, 0.14 μL 
Assay (A1, A2, C1 primers) Mix, H2O up to 10 μL total reaction volume. Genotyping plates were run on CFX384 
Touch Real-Time PCR Detection System (Biorad) using KASP manufacturer’s settings and cluster analysis visu-
alized with the Biorad CFX Manager 3.1 Allelic Discrimination Viewer.
Chromatin immunoprecipitation and quantitative allele-specific occupation (ChIPnQASO) 
assay. ChIP was performed as previously described with modifications25. In summary, 10 million cells were 
cross-linked with a 10 m incubation in 1% Formaldehyde. Cross-linking was quenched by 0.125 M Glycine incu-
bated for 5 m. Cells were pelleted and lysed via 15 m incubation in Cell Lysis Buffer (5 mM PIPES, 85 mM KCl, 
1% Igepal, 1x Protease Inhibitors (Pierce Protease Inhibitor Mini Tablets, Thermo Fisher Scientific); pH 8.0) on 
ice. Nuclei were pelleted and lysed via 30 m incubation in Nuclear Lysis Buffer (50 mM Tris-HCl, 10 mM EDTA, 
1% SDS; pH 8.0) on ice. DNA was sheared via sonication using the Bioruptor 2000 (Diagenode). For each ChIP, 3 
volumes of IP Dilution Buffer (16.7 mM Tris-HCl, 167 mM NaCl, 1.2 mM EDTA, 1.1% Triton × 100, 0.01% SDS, 
1x Protease Inhibitors; pH 8.0) was added to 20ug of chromatin and 2ug of antibody (TCF7L2 (D31H2); CTCF 
(C48H11), Cell Signaling Technology, Inc.). Chromatin was incubated with antibody at 4 C overnight on a rotat-
ing platform. Staph A cells were added to chromatin and rotated at room temp for 15 m. Chromatin-antibody 
complexes were pelleted and washed twice with Wash Buffer 1 (50 mM Tris-HCl, 2 mM EDTA, 0.2% Sarkosyl; 
pH 8.0) and four times with Wash Buffer 2 (100 mM Tri-HCl, 500 mM LiCl, 1% Igepal, 1% Deoxycholic Acid; 
pH 8.0). Immunoprecipitated chromatin was eluted in ChIP Elution Buffer (50 mM NaHCO3, 1% SDS) via 
15 m shaking at room temp. Crosslinks were reversed at 67 C overnight with 10% 5 M NaCl. Finally, immuno-
precipitated DNA was treated with 10ug RNase, incubated at 37 C for 20 m, and purified using QiaQuick PCR 
Purification Kit (Qiagen). KASP genotyping reactions (LGC Group) were performed in 384-well plate as follows: 
1 μL Immunoprecipitated or Input DNA, 5 μL 2x KASP Master Mix, 0.14 μL Assay (A1, A2, C1 primers) Mix, 
H2O up to 10 μL total reaction volume. Genotyping plates were run on CFX384 Touch Real-Time PCR Detection 
System (Biorad) using KASP manufacturer’s settings and cluster analysis visualized with the Biorad CFX Manager 
3.1 Allelic Discrimination Viewer. Allelic ratios were calculated by setting the Input DNA RFU values to 50% 
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allelic percentages and using the conversion factor to convert the Immunoprecipitated DNA RFU values to allelic 
percentages relative to input DNA. All ChIPnQASO reactions were performed in biological triplicate and stand-
ard deviation was calculated for each run.
Sensitivity titration assay of KASP system. Genomic DNA was extracted using the Quick-gDNA 
MiniPrep Kit (Genesee Scientific) from the parental HCT-116 cell line (G/G) and a modified isogenic clone pro-
duced from the pipeline that is heterozygous (G/T) for the risk SNP rs6983267. Genomic DNA was quantified by 
Nanodrop and the two genotypes mixed in varying ratios such that the mutant allele (T) was present at the follow-
ing percentages: 0%, 1%, 2.5%, 5%, 10%, 15%, 20%, 25%, 50%, with the 0% being the homozygous wildtype (G/G) 
control and 50% being the heterozygous (G/T) control genomic DNA. The 9 different ratios were then run on the 
KASP genotyping platform in 4 replicates as previously described with 10 ng of genomic DNA each. Statistical 
significance was calculated using Student’s t-test from replicates of each ratio sample against homozygous wild-
type control. We chose a stringent significance threshold of p < 0.001 to determine sensitivity of KASP platform to 
detect low levels of the mutant allele. From this, we determined the sensitivity threshold to be 5% mutant allele in 
a mixed population, meaning the KASP was able to detect the mutant allele at a frequency as low as 1 in 20 alleles 
or 1 heterozygous cell in a population of 10 cells.
Multi-cell-of-origin cell cloning method. For cell types with low HDR frequency, low transfection effi-
ciency or an inability to grow from single cells, we have developed a modified version of our pipeline to allow for 
multi-cell colony plating, growth and KASP genotype clone screening (Supplementary Fig. 8). Limiting dilution 
96-well plating was performed following the same methods as described in the single-cell plate seeding with the 
following exception: 1000 cells were added to 10 mL of fresh medium and distributed at a 100 μL volume per 
well using a multichannel pipette to plate cells at a 10-cell per well concentration. It is worth noting that while 
we plated at a 10-cell per well confluency, the highest number of cells per well actually observed was 5 or less, 
consistent with the 50% cell viability we observe with single-cell plating. Multi-cell clones grew and expanded 
faster than single-cell clones, requiring earlier media replacement. KASP genotyping was performed exactly as 
described previously. For multi-cell clones positive for correct HDR by KASP genotyping, TOPO TA cloning was 
required to confirm the presence of alleles with only the precise HDR event (free of NHEJ). TOPO TA cloning 
was performed using the TOPO TA Cloning for Sequencing Kit (Thermo Fisher Scientific) following manufac-
turer’s instructions. For each multi-cell clone, 24 to 32 TOPO TA colonies were screened via PCR amplification 
of inserted allele followed by confirmation of PCR products on a 1% agarose gel and purification using QiaQuick 
PCR Purification Kit (Qiagen). Of those, the TOPO TA colonies that produced a single PCR product of the cor-
rect size were submitted for Sanger Sequencing and analyzed using MacVector (MacVector, Inc.). For clones that 
are observed to contain HDR-only alleles, a second round of cell cloning is required to isolate single-cell clones 
if possible via single-cell plating of the positive multi-cell clone into 96-well plates following methods described 
previously.
References
 1. Freedman, M. L. et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 43, 513–518 (2011).
 2. Tak, Y. G. & Farnham, P. J. Making sense of GWAS: using epigenomics and genome engineering to understand the functional 
relevance of SNPs in non-coding regions of the human genome. Epigenetics Chromatin 8, 57 (2015).
 3. Foley, S. B. et al. Use of Whole Genome Sequencing for Diagnosis and Discovery in the Cancer Genetics Clinic. EBioMedicine 2, 
74–81 (2015).
 4. Cheon, J. Y., Mozersky, J. & Cook-Deegan, R. Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to 
come? Genome Med. 6, 121 (2014).
 5. Sur, I. K. et al. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science 338, 
1360–1363 (2012).
 6. Tak, Y. G. et al. Effects on the transcriptome upon deletion of a distal element cannot be predicted by the size of the H3K27Ac peak 
in human cells. Nucleic Acids Res. 44, 4123–4133 (2016).
 7. Cong, L. et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science (80-.) 339, 819 LP–823 (2013).
 8. Mali, P. et al. RNA-Guided Human Genome Engineering via Cas9. Science (80-.). 339, 823 LP–826 (2013).
 9. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
 10. Schwank, G. et al. Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients. Cell Stem 
Cell 13, (2013).
 11. Ousterout, D. G. et al. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne 
muscular dystrophy. Nat. Commun. 6, 6244 (2015).
 12. Richardson, C. D. et al. CRISPR-Cas9 Genome Editing In Human Cells Works Via The Fanconi Anemia Pathway. bioRxiv (2017).
 13. Ochiai, H. et al. TALEN-mediated single-base-pair editing identification of an intergenic mutation upstream of BUB1B as causative 
of PCS (MVA) syndrome. Proc. Natl. Acad. Sci. 111, 1461–1466 (2014).
 14. Gu, H., Zou, Y.-R. & Rajewsky, K. Independent control of immunoglobulin switch recombination at individual switch regions 
evidenced through Cre-loxP-mediated gene targeting. Cell 73, 1155–1164 (1993).
 15. Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862 (2016).
 16. Sahasrabudhe, R. et al. Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in 
Patients With Gastric Cancer. Gastroenterology 152, 983–986.e6 (2017).
 17. Tomlinson, I. et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. 
Nat Genet 39, 984–988 (2007).
 18. Jin, H.-J., Jung, S., DebRoy, A. R. & Davuluri, R. V. Identification and validation of regulatory SNPs that modulate transcription 
factor chromatin binding and gene expression in prostate cancer. Oncotarget 7, 54616–54626 (2016).
 19. Cavalli, M. et al. Allele-specific transcription factor binding to common and rare variants associated with disease and gene 
expression. Hum. Genet. 135, 485–497 (2016).
 20. Pomerantz, M. M. et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat. 
Genet. 41, 882–884 (2009).
 21. Wright, J. B., Brown, S. J. & Cole, M. D. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-
associated single-nucleotide polymorphism in colorectal cancer cells. Mol. Cell. Biol. 30, 1411–20 (2010).
www.nature.com/scientificreports/
9SCientifiC REPORtS | 7: 15044  | DOI:10.1038/s41598-017-15407-4
 22. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Corn, J. E. Enhancing homology-directed genome editing by catalytically 
active and inactive CRISPR-Cas9 using asymmetric donorDNA. Nat Biotech 34, 339–344 (2016).
 23. Miyaoka, Y. et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat Meth 11, 291–293 (2014).
 24. Spisak, S. et al. CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. Nat 
Med 21, 1357–1363 (2015).
 25. O’Geen, H., Frietze, S. & Farnham, P. J. Using ChIP-seq Technology to Identify Targets of Zinc Finger Transcription Factors. in 
Engineered Zinc Finger Proteins: Methods and Protocols (eds. Mackay, J. P. & Segal, D. J.) 437–455, https://doi.org/10.1007/978-1-
60761-753-2_27 (Humana Press, 2010).
Acknowledgements
This work was supported by US National Institutes of Health awards R21 CA204563 to D.J.S and R21 CA199631 
and K12 CA138464 to L.G.C.C., and by the V Foundation from Cancer Research to L.G.C.C.
Author Contributions
L.G.C.C., D.J.S., and N.B.C. conceived the project. N.B.C., J.S., and H.O’G designed and performed the 
experiments. L.G.C.C., D.J.S., and N.B.C. wrote the manuscript with input from all authors.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-15407-4.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
